6-cyclohexyl-hexanoic acid amide | 4354-53-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-cyclohexyl-hexanoic acid amide
• 英文别名: 6-Cyclohexyl-hexansaeure-amid；6-Cyclohexyl-capronsaeure-amid；6-Cyclohexylhexanamide
• CAS: 4354-53-4
• 化学式: C₁₂H₂₃NO
• mdl: MFCD03931161
• 分子量: 197.321
• InChiKey: BZXHFNXFQKMYFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.916
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-cyclohexyl-hexanoic acid amide 在 sodium metabisulfite 、 三氯氧磷 作用下， 生成 6-cyclohexyl-hexanenitrile
  参考文献：
  名称：

  Ketimines. III. ι-Cyclohexylalkyl Alkyl Type¹

  摘要：

  DOI：

  10.1021/ja01145a016
• 作为产物：
  描述：

  6-cyclohexyl-hexanoyl chloride 在 氨 作用下， 生成 6-cyclohexyl-hexanoic acid amide
  参考文献：
  名称：

  Stetter et al., Chemische Berichte, 1953, vol. 86, p. 1308,1311

  摘要：

  DOI：

文献信息

• [EN] AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE<br/>[FR] COMPOSÉS AMINO HÉTÉROARYLES COMME MODULATEURS DE LA BÊTA-SECRÉTASE ET PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2011063233A1

  公开（公告）日：2011-05-26

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein ring A, B1, B2, B3, L, R1, R4, R5 and m of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

  本发明涵盖了一类新化合物，用于调节β-分泌酶酶活性，治疗由β-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一个实施例中，这些化合物具有一般的化学式I，其中化合物I的环A、B1、B2、B3、L、R1、R4、R5和m在此定义。该发明还包括将这些化合物用于制备药物组合物，用于治疗与β-分泌酶蛋白活性相关的疾病和症状，包括例如阿尔茨海默病（AD）、认知缺陷、认知损害、精神分裂症和其他与大脑斑块形成和/或沉积有关和/或由此引起的中枢神经系统疾病。该发明还包括化合物I的进一步实施例、中间体和用于制备化合物I的过程。
• 5-Amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of beta-amyloid protein production
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0778266A1

  公开（公告）日：1997-06-11

  A series of 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives of Formula I have been synthesized. As inhibitors of the production of β-amyloid protein from β-amyloid precursor protein, these compounds are expected to be effective in treating patients suffering from or susceptible to conditions or disorders linked to brain accumulation of β-amyloid protein; e.g., Alzheimer's Disease and Down's Syndrome.

  一系列5-氨基-6-环己基-4-羟基-己酰胺衍生物式I已经被合成。作为β-淀粉样前体蛋白产生的抑制剂，这些化合物被认为对于治疗患有或易感患有与β-淀粉样蛋白脑积累相关的疾病或症状，例如阿尔茨海默病和唐氏综合症的患者是有效的。
• Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use
  申请人：Cheng Yuan

  公开号：US20120329830A1

  公开（公告）日：2012-12-27

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein ring A, B 1 , B 2 , B 3 , L, R 1 , R 4 , R 5 and m of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

  本发明涉及一类新的化合物，可用于调节β-分泌酶酶活性和治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施例中，所述化合物具有一般式I，其中环A、B1、B2、B3、L、R1、R4、R5和m在本文中有定义。本发明还包括使用这些化合物制备药物组合物，用于治疗与β-分泌酶蛋白活性相关的疾病和症状，例如阿尔茨海默病（AD）、认知缺陷、认知障碍、精神分裂症以及与大脑斑块形成和/或沉积相关和/或由其引起的其他中枢神经系统疾病。本发明还包括式I的进一步实施例、中间体和用于制备式I化合物的过程。
• THE REACTION OF NITRILES WITH HYDRAZOIC ACID: SYNTHESIS OF MONOSUBSTITUTED TETRAZOLES
  作者：JOSEPH S. MIHINA、ROBERT M. HERBST

  DOI：10.1021/jo01151a027

  日期：1950.9
• [EN] AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS<br/>[FR] AMINOALCAMIDES POUR UNE UTILISATION DANS LE TRAITEMENT DE MALADIES INFLAMMATOIRES, DÉGÉNÉRATIVES OU DÉMYÉLINISANTES DU SYSTÈME NERVEUX CENTRAL
  申请人：NENSIUS RES AS

  公开号：WO2011000945A9

  公开（公告）日：2011-04-07